Al-Moundhri MS, Al-Shukaili A, Al-Nabhani M, Al-Bahrani B, Burney I, Rizivi A, Ganguly S. Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma. World J Gastroenterol 2008; 14(24): 3879-3883
Corresponding Author of This Article
Dr. Mansour S Al-Moundhri, Associate Professor and Consultant Oncologist, Department of Medicine, College of Medicine, Sultan Qaboos University, PO Box 35, Muscat 123, Oman. email@example.com
Article-Type of This Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jun 28, 2008; 14(24): 3879-3883 Published online Jun 28, 2008. doi: 10.3748/wjg.14.3879
Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma
Mansour S Al-Moundhri, A Al-Shukaili, M Al-Nabhani, B Al-Bahrani, IA Burney, A Rizivi, SS Ganguly
Mansour S Al-Moundhri, M Al-Nabhani, IA Burney, A Rizivi, Medical Oncology Unit, Department of Medicine, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat 123, Oman
A Al-Shukaili, Department of Microbiology and Immunology (SQU), Muscat 123, Oman
B Al-Bahrani, National Cancer Institute, Royal Hospital, Muscat 123, Oman
SS Ganguly, Department of Epidemiology and Medical Statistics (SQU), Muscat 123, Oman
ORCID number: $[AuthorORCIDs]
Author contributions: Al-Moundhri MS designed the research project and wrote the manuscript; Al-Moundhri MS, Al-Bahrani B, Burney IA, Rizivi A provided patient samples; Al-Shukaili A, Al-Nabhani M performed the research assay; Ganguly SS, Al-Moundhri MS performed data analysis and interpretation; Al-Bahrani B, Burney IA reviewed the manuscript.
Correspondence to: Dr. Mansour S Al-Moundhri, Associate Professor and Consultant Oncologist, Department of Medicine, College of Medicine, Sultan Qaboos University, PO Box 35, Muscat 123, Oman. firstname.lastname@example.org
Received: March 26, 2008 Revised: May 19, 2008 Accepted: May 26, 2008 Published online: June 28, 2008
AIM: To analyze the serum levels and prognostic significance of vascular endothelial growth factor (VEGF) -A, -C, and -D, and their receptors, VEGFR-1 and -2 in gastric adenocarcinomas.
METHODS: The serum levels of VEGF family members were measured in 76 control subjects and 76 patients with gastric adenocarcinoma using an enzyme-linked immunosorbent assay (ELISA). These measurements were correlated with clinco-pathological features and survival rates.
RESULTS: The serum levels of VEGF-A and its receptor, VEGFR-1, were significantly higher in patients with gastric cancer than in healthy donors (t = 2.3, P = 0.02 and t = 4.2, P < 0.0001, respectively). In contrast, the serum levels of VEGF-D were significantly higher in control subjects than in patients (t = 2.9, P = 0.004). There was no significant difference in serum levels of VEGF-C and VEGFR-2 between patients and controls. VEGF-C was associated with advanced tumor stage and presence of metastasis. VEGFR-1 was associated with metastasis, advanced overall stage, tumor differentiation and survival. VEGFR-2 levels were associated with poor tumor differentiation. There was no significant prognostic value for any of the VEGF family members or their receptors except for VEGFR-1 where high levels were associated with a poor overall survival.
CONCLUSION: Serum VEGF levels vary significantly in the same cohort of patients with variable clinico-pathological features and prognostic values. The simultaneous measurement of VEGF receptors levels in sera may overcome the limitations of a single biomarker assay.
Citation: Al-Moundhri MS, Al-Shukaili A, Al-Nabhani M, Al-Bahrani B, Burney I, Rizivi A, Ganguly S. Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma. World J Gastroenterol 2008; 14(24): 3879-3883
Gastric cancer is the second most common cancer worldwide and remains a global health burden. The prognosis of patients with gastric cancer has been shown to be influenced by established surgical-pathological features, such as pathological stage, location of the tumor, and histological type and grade of the tumor[2–4]. In comparison, the intense search for predictive molecular biomarkers has not yet translated into clinical use[5–7].
There is growing recognition of the central role that the vascular endothelial growth factor (VEGF) family plays in angiogenesis in which the formation of new blood vessels is necessary for the growth and spread of tumors. The VEGF family consists of seven members-VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F, and placental growth factor (PlGF)-which share eight cysteine residues in a VEGF homology domain. The members act through specific tyrosine kinase receptors, VEGFR-1, -2 and -3. VEGF-A acts through VEGFR-1 and -2 receptors, VEGF-C and -D act through VEGFR-2 and -3.
Studies have shown an association between intratu-moral microvessel density and tumor aggressiveness in gastric cancer. Among angiogenic stimulators, VEGF-A plays an essential role in both vasculogenesis and angiogenesis. Serum concentrations of VEGF-A have been examined in patients with gastric cancer and a relationship between the serum concentration of VEGF and metastasis and/or poor outcome has been demonstrated. However, the significance of other VEGF family members (VEGF-B, -C, and -D) in tumor angiogenesis and metastasis are not fully demonstrated. Recently, the prognostic importance of serum concentrations of other VEGF family members (VEGF-C and -D and their receptors) in gastric cancer has been reported. Overall, these studies were limited to one or two VEGF family members and their receptors and did not examine the full profile of expression of these proteins in the same patient.
In the current study, we evaluated the serum levels of VEGF-A, -C, and -D, and their receptors, VEGFR-1 and -2 in both healthy controls and gastric cancer patients. We then correlated these serum levels with clinico-pathological features and patient survival rates.
MATERIALS AND METHODS
The study population consisted of a series of unrelated patients diagnosed with gastric cancer in three main hospitals in the Sultanate of Oman (Sultan Qaboos University Hospital, Royal Hospital, and Sohar Hospital). The control group was composed of subjects of the same ethnic and geographical origin as the patients. The Medical Research and Ethics Committee of the College of Medicine of Sultan Qaboos University approved the study design. The study subjects gave an informed consent prior to participation in the study.
Serum VEGF family level assay
Peripheral venous blood samples were obtained prior to any treatment and allowed to clot at room temperature and centrifuged at 2000 g for 10 min. Sera were separated, aliquoted, and stored at -70°C until assay. Serum VEGF concentrations were determined using a commercially available enzyme-linked immunoassay (ELISA) designed to measure VEGF-A (VEGF 165), VEGF-C, VEGF-D, VEGFR-1, and VEGFR-2 levels (Quantikine, R&D Systems Europe, Abingdon, UK). Assays employed the quantitative sandwich enzyme immunoassay and were performed according to the manufacturer’s procedure.
The significance of differences in the levels of various VEGF molecules between patients and controls was studied using the unpaired t test and further confirmed with Mann-Whitney U test. The significance of the correlations between the expression of various VEGF proteins and clinico-pathological features was evaluated by the Spearman’s correlation test.
Overall survival rates were determined from the time of biopsy-proven diagnosis until either the time of death or last known follow-up examination. The dates of death were obtained from either medical records or phone contact. The Kaplan-Meier method was used to estimate overall survival time, and the statistical significance was determined by log-rank test. Backward conditional Cox proportional hazards regression model was utilized for multivariate analyses where age (≤ 40 years, > 40 years), gender, proximal or distal location, histological classification (intestinal vs non-intestinal), T stage (1 + 2 vs 3 + 4), presence or absence of lymph node metastasis, overall all stage (I + II vs III + IV), tumor differentiation (well vs moderate + poor), all the VEFG factors were included. P values less than 0.05 were considered statistically significant. Analysis of data was performed using SPSS 10.0 software.
A total of 76 gastric cancer patients and 76 unrelated controls were included. The age range for the participants included in the study was 21-82 years; the mean and standard deviation of ages for the patients and controls were 55.7 ± 11.3 and 38.5 ± 10.2 years, respectively. The proportion of males (n = 41) and females (n = 35) were equal in both groups. Fifty four patients received either chemotherapy alone or chemoradiotherapy.
The serum values of VEGF-A, -C, -D, and VEGFR-1 and -2 in patients and controls
Table 1 shows the mean, standard deviation, median, and ranges of serum levels of VEGF-A, -C, and -D, and VEGFR-1 and -2 in patients with gastric cancer and controls. The serum VEGF-A and VEGFR-1 levels were significantly higher in patients with gastric cancer than in healthy donors (P = 0.02 and 0.0001, respectively). Interestingly, the serum levels of VEGF-D were higher in controls than in patients with gastric cancer. There was no significant difference in serum levels of VEGF-C and VEGFR-2 between patients and controls.
Table 1 Serum concentrations (pg/mL) of VEGF-A, -C, and -D, and VEGFR-1 and -2 in patients with gastric adenocarcinoma and control subjects (n=76).
The association between serum values of VEGF-A, -C, -D, and VEGFR-1 and -2 and clinico-pathological features
Table 2 shows the association between serum values of VEGF-A, -C, -D and VEGFR-1 and -2 and clinico-pathological features. VEGF-C was associated with advanced tumor stage and presence of metastasis. VEGFR-1 was associated with metastasis, advanced overall tumor stage, and tumor differentiation. VEGFR-2 levels were associated with poor tumor differentiation.
Table 2 Associations between serum concentrations (pg/mL) of VEGF-A, -C, and -D, and VEGFR-1 and -2 and clinco-pathological features in 76 patients of gastric adenocarcinoma and 76 control subjects (mean ± SD ).
bP < 0.01 vs determined in patients who had surgical resections (n = 58).
Correlation between circulating VEGF levels and patient survival
Elevated serum VEGF levels were defined as greater than the 95th percentile in the healthy control group as previously described. There was no significant predictive value for any of the VEGFs or their receptors (data not shown) except for VEGFR-1 as shown in Figure 1. The median survival time for patients with high and low levels of VEGFR-1 was 5 mo (95% CI 2.6-7.4) and 13 mo (95% CI 1.4-24.6), respectively. The 5-year survival rates were 20% and 36%, respectively (P = 0.02). Multivariate regression analysis showed that only advanced stage III and IV (Hazard ratio 6.7; 95% CI, 2.2 -20.0; P = 0.001) to be a significant independent factor.
Figure 1 Kaplan-Meier survival curves in relation to serum VEGFR-1 levels in 76 patients with gastric adenocarcinoma.1Elevated serum VEGFR-1 levels were defined as greater than the 95th percentile in the healthy control group.
Studies on the role of the VEGF family in gastric cancer have focused on individual VEGF members and their respective receptors. The evaluation of the simultaneous expression of VEGF family members and their receptors may provide more accurate prognostic information. Therefore, we have investigated the serum levels of VEGF-A, -C, -D, and VEGFR-1 and -2 and studied their predictive and prognostic significance in the same group of patients.
In the present study, the VEGF-A and VEGFR-1 levels are higher in patients with gastric cancer than in healthy controls, which is consistent with results from other studies. However, we found that serum VEGF-D levels were higher in the control group than in patients with gastric cancer. George et al studied VEGF-A, -C, and -D mRNA tissue expression in colorectal cancer progression, demonstrating that VEGF-D mRNA remained at persistently low levels in carcinomas compared with adenomas, and that both VEGFR-2 and VEGFR-3 mRNA expression levels remained constant. This result suggested that VEGF-D acts as a competitive agonist with VEGF-A and VEGF-C; a decrease in VEGF-D levels may allow increased access of VEGF-A and VEGF-C, which are more potent angiogenic cytokines than VEGF-D, to the two VEGF receptors. It has been previously shown that tissue expression of certain VEGF family members correlates with their serum levels. Therefore, the advanced tumor stage presentation that predominated in the current cohort of patients may have led to the differential expression of the VEGF family members, further emphasizing the importance of the simultaneous measurement of these factors.
The correlation of markers of angiogenesis and clinico-pathological features further highlights the complex interaction between various factors and their respective receptors. Whereas VEGF-A and -D did not correlate with any of the clinico-pathological features studied, it is interesting to note the strong association between VEGFR-1 and advanced stage cancer, the presence of metastasis, and poor tumor differentiation. VEGF-C was a serum biomarker for advanced tumor stage and poor differentiation, whereas VEGFR-2 correlated with poor tumor differentiation. It is interesting that serum VEGF-C and -D levels did not correlate with lymph node metastasis, a result that has been shown previously. This finding is most likely due to the fact that most patients included had lymph node metastasis and, therefore, such differences could not be found (Table 2).
The available data on the prognostic significance of serum VEGF levels in malignancies is controversial[24–26]. The prognostic significance of VEGF (in particular, of VEGF-A), as determined by ELISA, has been commonly studied in various tumors[24–27]. It has been shown that high serum VEGF levels correlate with poor prognosis in certain hematological malignancies. In gastric cancer, it has been shown that serum VEGF-A levels correlated with local tumor extent, disease stage, and the presence of distant metastases, and is an independent prognostic factor for patient survival. Recently, Wang et al reported that serum VEGF-C levels might be a useful biomarker to determine the presence of lymph node metastasis in patients with gastric cancer as well as correlate with VEGF-C tissue expression. Juttner et al showed that both VEGF-D and VEGFR-3 are independent prognostic biomarkers to identify patients with poor prognosis after curative resection of gastric adenocarcinomas; when combined with an analysis of VEGF-C, patients with shorter survival times could be predicted. In the current study, a significant correlation between VEGFR-1 and advanced tumor stage, presence of metastasis, and poor tumor differentiation in turn reflects poor survival outcome as shown in Figure 1. To our knowledge, this is the first study to report on the prognostic significance of serum VEGFR-1 levels in patients with gastric cancer. It has been suggested that the VEGFR-1/VEGF ratio in sera may be of greater prognostic value than VEGF levels alone, hence, overcoming the limitations of a single biomarker assay.
In conclusion, we have demonstrated that there are significant variations in VEGF serum concentrations when measured simultaneously that correlate with important variations in clinico-pathological features and prognostic significance. Future work will address the application of this concept on a larger cohort of patients to generate a predictive profile that examines the simultaneous expression of these proteins at the tissue level.
The prognostic importance of serum concentrations of vascular endothelial growth factor (VEGF) family members in gastric cancer has been reported. Overall, these studies were limited to one or two VEGF family members and their receptors and did not examine the full profile of expression of these proteins in the same patient. In the current study, authors evaluated the serum levels of VEGF-A, -C, and -D, and their receptors, VEGFR-1 and -2 in both healthy controls and gastric cancer patients. They then correlated these serum levels with clinico-pathological features and patient survival rates.
To date, the prognostic value of simultaneous measurement of serum concentration several VEGF family proteins in gastric cancer remains unclear. The variation of serum concentration of various VEGF family members in the same patient may provide useful predictive and prognostic tool.
Innovations and breakthroughs
In the present study, the authors measured the serum levels of VEGF-A, -C, and -D, and their receptors, VEGFR-1 and -2. This is the first study that measures serum level of VEGF family members simultaneously. The serum levels of VEGF-A and its receptor, VEGFR-1, were significantly higher in patients with gastric cancer than in healthy donors. In contrast, the serum levels of VEGF-D were significantly higher in control subjects than in patients. VEGFR-1 was associated with metastasis, advanced overall stage, tumor differentiation and survival. The result suggests that levels of VEGF family members may vary significantly and that simultaneous pre-operative measurement may provide a more accurate prognostic tool.
The results of the present study demonstrate the variation in VEGF family members when measured simultaneously. The measurement of all these proteins may provide more accurate predictive and prognostic information.
Angiogenesis is a physiological process in the body that involves the formation of new blood vessels. VEGF family plays an important role in angiogenesis. The VEGF family consists of seven members-VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F, and placental growth factor. The members act through specific tyrosine kinase receptors-VEGFR-1, -2 and -3. VEGF-A acts through VEGFR-1 and -2 receptors; VEGF-C and -D act through VEGFR-2 and -3.
This is an interesting paper. Authors analyzed the serum levels and prognostic significance of VEGF-A, -C, and -D, and their receptors, VEGFR-1 and -2 in gastric adenocarcinomas.
Supported by a grant from Sultan Qaboos University Research Fund
Anderson C, Nijagal A, Kim J. Molecular markers for gastric adenocarcinoma: an update.Mol Diagn Ther. 2006;10:345-352.
Al-Moundhri MS, Al-Bahrani B, Burney IA, Nirmala V, Al-Madhani A, Al-Mawaly K, Al-Nabhani M, Thomas V, Ganguly SS, Grant CS. The prognostic determinants of gastric cancer treatment outcome in Omani Arab patients.Oncology. 2006;70:90-96.
Miyahara R, Niwa Y, Matsuura T, Maeda O, Ando T, Ohmiya N, Itoh A, Hirooka Y, Goto H. Prevalence and prognosis of gastric cancer detected by screening in a large Japanese population: data from a single institute over 30 years.J Gastroenterol Hepatol. 2007;22:1435-1442.
Barchielli A, Amorosi A, Balzi D, Crocetti E, Nesi G. Long-term prognosis of gastric cancer in a European country: a population-based study in Florence (Italy). 10-year survival of cases diagnosed in 1985-1987.Eur J Cancer. 2001;37:1674-1680.
Al-Moundhri MS, Nirmala V, Al-Hadabi I, Al-Mawaly K, Burney I, Al-Nabhani M, Thomas V, Ganguly SS, Grant C. The prognostic significance of p53, p27 kip1, p21 waf1, HER-2/neu, and Ki67 proteins expression in gastric cancer: a clinicopathological and immunohistochemical study of 121 Arab patients.J Surg Oncol. 2005;91:243-252.
Mihmanli M, Dilege E, Demir U, Coskun H, Eroglu T, Uysalol MD. The use of tumor markers as predictors of prognosis in gastric cancer.Hepatogastroenterology. 2004;51:1544-1547.
Boku N, Ohtsu A, Yoshida S, Shirao K, Shimada Y, Hyodo I, Saito H, Miyata Y. Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin.Jpn J Clin Oncol. 2007;37:275-281.
Hormbrey E, Gillespie P, Turner K, Han C, Roberts A, McGrouther D, Harris AL. A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful?Clin Exp Metastasis. 2002;19:651-663.
Otrock ZK, Makarem JA, Shamseddine AI. Vascular endothelial growth factor family of ligands and receptors: review.Blood Cells Mol Dis. 2007;38:258-268.
Moreira IS, Fernandes PA, Ramos MJ. Vascular endothelial growth factor (VEGF) inhibition--a critical review.Anticancer Agents Med Chem. 2007;7:223-245.
Simiantonaki N, Taxeidis M, Jayasinghe C, Kirkpatrick CJ. Epithelial expression of VEGF receptors in colorectal carcinomas and their relationship to metastatic status.Anticancer Res. 2007;27:3245-3250.
Zhao HC, Qin R, Chen XX, Sheng X, Wu JF, Wang DB, Chen GH. Microvessel density is a prognostic marker of human gastric cancer.World J Gastroenterol. 2006;12:7598-7603.
Zhou Y, Ran J, Tang C, Wu J, Honghua L, Xingwen L, Ning C, Qiao L. Effect of celecoxib on E-cadherin, VEGF, Microvessel density and apoptosis in gastric cancer.Cancer Biol Ther. 2007;6:269-275.
Aoyagi K, Kouhuji K, Yano S, Miyagi M, Imaizumi T, Takeda J, Shirouzu K. VEGF significance in peritoneal recurrence from gastric cancer.Gastric Cancer. 2005;8:155-163.
Karayiannakis AJ, Syrigos KN, Polychronidis A, Zbar A, Kouraklis G, Simopoulos C, Karatzas G. Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery.Ann Surg. 2002;236:37-42.
Oh SY, Kwon HC, Kim SH, Jang JS, Kim MC, Kim KH, Han JY, Kim CO, Kim SJ, Jeong JS. Clinicopathologic significance of HIF-1alpha, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer.BMC Cancer. 2008;8:123.
Juttner S, Wissmann C, Jons T, Vieth M, Hertel J, Gretschel S, Schlag PM, Kemmner W, Hocker M. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma.J Clin Oncol. 2006;24:228-240.
Wang TB, Deng MH, Qiu WS, Dong WG. Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer.World J Gastroenterol. 2007;13:1794-1797; discussion 1797-1798.
Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients.Melanoma Res. 2006;16:405-411.
Ding S, Lin S, Dong X, Yang X, Qu H, Huang S, Liu W, Zhou L, Liu D. Potential prognostic value of circulating levels of vascular endothelial growth factor-A in patients with gastric cancer.In Vivo. 2005;19:793-795.
Ohta M, Konno H, Tanaka T, Baba M, Kamiya K, Syouji T, Kondoh K, Watanabe M, Terada H, Nakamura S. The significance of circulating vascular endothelial growth factor (VEGF) protein in gastric cancer.Cancer Lett. 2003;192:215-225.
George ML, Tutton MG, Janssen F, Arnaout A, Abulafi AM, Eccles SA, Swift RI. VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression.Neoplasia. 2001;3:420-427.
Kondo K, Kaneko T, Baba M, Konno H. VEGF-C and VEGF-A synergistically enhance lymph node metastasis of gastric cancer.Biol Pharm Bull. 2007;30:633-637.
Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer.Cancer Invest. 2006;24:576-580.
Vincenzi B, Santini D, Russo A, Gavasci M, Battistoni F, Dicuonzo G, Rocci L, Rosaria VM, Gebbia N, Tonini G. Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan.Pharmacogenomics. 2007;8:319-327.
Poon RT, Lau CP, Cheung ST, Yu WC, Fan ST. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma.Cancer Res. 2003;63:3121-3126.
Wierzbowska A, Robak T, Wrzesien-Kus A, Krawczynska A, Lech-Maranda E, Urbanska-Rys H. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia.Eur Cytokine Netw. 2003;14:149-153.
Poreba M, Jazwiec B, Kuliczkowski K, Poreba R. [Circulating endothelial cells, endothelial precursors, VEGF and bFGF concentrations in patients with acute leukemias, lymphomas and myelomas].Pol Arch Med Wewn. 2005;113:27-34.
Jacobsen J, Grankvist K, Rasmuson T, Ljungberg B. Prognostic importance of serum vascular endothelial growth factor in relation to platelet and leukocyte counts in human renal cell carcinoma.Eur J Cancer Prev. 2002;11:245-252.